Fulcrum Therapeutics Azioni (NASDAQ: FULC)

Ultime notizie per Fulcrum Therapeutics (NASDAQ:FULC) Azioni

Fulcrum Therapeutics

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics Inc

IonQ Inc.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares are barreling higher Thursday after the company reported better-than-expected third-quarter results and announced a series of partnerships. Multiple analysts raised price targets following the print, which appears to be adding to the upward momentum. Here&#8217;s <a href="https://www.benzinga.com/news/earnings/24/11/41789866/ionq-q3-earnings-revenue-beat-eps-miss-bookings-jump-on-air-force-research-contract-guidance-raise-">what you need to know.</a>
What To Know: IonQ reported third-quarter revenue of $12.4 million, beating analyst expectations of $10.56 million. The company posted a loss of 24 cents per share, versus an expected loss of 21 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue grew 102% year-over-year, and the company saw $63.5 million in new bookings, bolstered by a $54.5 million contract with the U.S. Air Force Research Lab (AFRL) to enhance quantum hardware for scaling and networking applications.
IonQ also raised its full-year 2024 revenue forecast to a range of $38.5 million to $42.5 million, up from a previous range of $38 million to $42 million.
Following the company&#8217;s quarterly results, Benchmark analyst David Williams maintained IonQ with a Buy and raised the price target from $12 to $22. Needham analyst Quinn Bolton also maintained a Buy rating and raised the price target from $13 to $18.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814589/why-trumps-boost-to-treasury-yields-inflation-expectations-may-weaken-feds-efforts-">Why Trump&#8217;s Boost To Treasury Yields, Inflation Expectations May Weaken Fed&#8217;s Efforts To Cut Interest Rates</a>
What Else: IonQ announced the creation of a new quantum application development center in collaboration with AstraZeneca. The companies will partner on the development of quantum applications.
IonQ also announced partnerships with Ansys and NKT Photonics. The company will work with Ansys to integrate quantum computing into the computer-aided engineering industry. IonQ said it will work with NKT Photonics to develop next-generation laser systems for its trapped-ion quantum computers and networking equipment.
&#8220;We are pleased to partner with NKT Photonics as they share IonQ&#8217;s vision of developing high-performing, scalable and accessible quantum computers designed for enterprise data center environments,&#8221; said Dave Mehuys, vice president of product engineering at IonQ.
Finally, IonQ announced that it entered into a definitive agreement to acquire California-based quantum networking company Qubitekk. The acquisition is expected to close in the next six months. As part of the transaction, the Qubitekk team will join IonQ to further IonQ&#8217;s position in the quantum networking industry. 
IONQ Price Action: IonQ shares were up 35.7% at $22.33 at the time of publication, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07112406/ionq-1024x534.png" alt="" class="wp-image-635746" style="width:454px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07112406/ionq-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07112406/ionq-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07112406/ionq-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07112406/ionq.png 1162w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41814454/donald-trump-could-pardon-ross-ulbricht-january-6-protestors-and-one-other-controversial-f">Donald Trump Could Pardon Ross Ulbricht, January 6 Protestors And One Other Controversial Figure, Polymarket Traders Speculate</a></li>
</ul>
Image Via Shutterstock.

Earnings

News

Movers

IONQ

IonQ Stock Is Soaring Thursday: What's Going On?

JP Morgan analyst Cory Carpenter maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Neutral and raises the price target from $160 to $200.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on AppLovin, Raises Price Target to $200

Baird analyst Timothy Wojs maintains Fortune Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBIN#NYSE">FBIN</a>) with a Neutral and lowers the price target from $94 to $90.

FBIN

Baird Maintains Neutral on Fortune Brands, Lowers Price Target to $90

US Foods Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) reported third-quarter adjusted earnings per share of 85 cents,<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41801904/us-foods-reports-third-quarter-fiscal-year-2024-earnings" rel="noreferrer noopener"> beating the street view of 83 cents.</a> Quarterly sales of $9.728 billion (+6.8%) outpaced the analyst consensus estimate of $9.718 billion,&nbsp;driven by total case volume growth and food cost inflation of 3.2%.
&#8220;We delivered strong results in the&nbsp;third quarter&nbsp;despite the softer macro environment and weather-related challenges which pressured industry case volumes,&#8221; said Dave Flitman, CEO.
In its latest quarterly earnings, US Foods reported a 3.8% increase in total case volume, with independent restaurant case volume rising by 4.1%. The company&#8217;s gross profit grew by 8.1%, reaching $1.7 billion.
Net income for the quarter was $148 million, while adjusted EBITDA increased 13.2% to $455 million.
Adjusted gross profit was $1.7 billion, an increase of 7.0% from the prior year. Adjusted gross profit as a percentage of net sales was 17.4%.
Also Read:<a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41812800/papa-johns-earns-less-dough-as-q3-sales-dip-ceo-blames-challenging-consumer-environment" rel="noreferrer noopener"> Papa John&#8217;s Earns Less Dough As Q3 Sales Dip, CEO Blames &#8216;Challenging Consumer Environment&#8217;</a>
Net debt at the end of the third quarter of fiscal year 2024 was $4.7 billion. The company exited the quarter with cash and equivalents worth $81 million. Long-term debt as of quarter-end totaled $4.671 billion.
At the end of the third quarter, the company had approximately $398 million in remaining funds authorized under its $1 billion share repurchase program.
&#8220;In the face of the softer macro backdrop, we continue to grow sales, expand margins and deploy our strong free cash flow,&#8221; said Dirk Locascio, CFO. &#8220;Additionally, we allocated $580 million of capital during the quarter toward share repurchases while maintaining a strong balance sheet.&#8221;
Outlook: US Foods Holding tightened its FY24 net sales outlook to $37.7 billion &#8211; $38.0 billion, compared to the prior view of $37.5 billion &#8211; $38.5 billion and the <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst estimate of $37.84 billion.</a>
The company also projects adjusted diluted earnings per share of $3.05 &#8211; $3.15, narrower than the prior view of $3.00 &#8211; $3.20, compared with the $3.08 estimate.
Price Action: USFD shares are trading higher by 0.36% to $66.04&nbsp;at last check Thursday.
Also Read:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41806970/hersheys-q3-earnings-sour-as-sales-dip-and-outlook-darkens-ceo-pledges-aggressive-turnaround-amid-h" target="_blank" rel="noreferrer noopener">Hershey&#8217;s Q3 Earnings Sour As Sales Dip And Outlook Darkens; CEO Pledges Aggressive Turnaround Amid High Cocoa Costs</a></li>
</ul>

Equities

Guidance

Markets

General

USFD

US Foods Beats Q3 Expectations As Sales And Case Volumes Surge, Tightens FY24 Outlook

Baird analyst David Tarantino maintains Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) with a Neutral and raises the price target from $37 to $46.

BROS

Baird Maintains Neutral on Dutch Bros, Raises Price Target to $46

<a href="https://www.gevernova.com/news/press-releases/ge-vernova-expands-strategic-collaboration-agreement-aws-help-energy-companies" title="https://www.gevernova.com/news/press-releases/ge-vernova-expands-strategic-collaboration-agreement-aws-help-energy-companies">https://www.gevernova.com/news/press-releases/ge-vernova-expands-strategic-collaboration-agreement-aws-help-energy-companies</a>

AMZN

GE Vernova Expands Collaboration With AWS To Accelerate Energy Transition, Integrating Asset Performance Management And CERius Software On AWS Cloud

Nexstar Media Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXST#NASDAQ">NXST</a>) shares are trading higher. The company reported a third-quarter fiscal year 2024 net revenue increase of 20.7% year over year to $1.366 billion. That&#8217;s <a href="https://www.benzinga.com/pressreleases/24/11/b41802369/nexstar-media-group-reports-record-third-quarter-net-revenue-of-1-37-billion" target="_blank" rel="noreferrer noopener">in line with the consensus</a>.
<ul>
<li>Revenues from Advertising rose&nbsp;22.2% to&nbsp;$622 million. The growth was led by a $135 million year-over-year rise in election-year political advertising.</li>
<li>Distribution revenue gained&nbsp;20.2% to&nbsp;$719&nbsp;million. This growth was driven by the resolution of a 2023 MVPD dispute, favorable contract renewals, annual rate increases, higher vMVPD subscribers, new CW affiliations, and the return of partner stations.</li>
<li>Adjusted EBITDA jumped&nbsp;82.8% Y/Y to&nbsp;$510 million, and the margin expanded to&nbsp;37.3% from&nbsp;24.6% a year ago.</li>
<li>EPS was&nbsp;$5.27, up from&nbsp;$0.70 in the prior year quarter but&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">below the consensus of&nbsp;$5.40.</a></li>
<li>Adjusted free cash flow totaled&nbsp;$327 million, up from&nbsp;$81 million in the prior year quarter. As of September 30, 2024, unrestricted cash stood at&nbsp;$181 million.</li>
</ul>
Buyback: The company repurchased shares worth $178&nbsp;million in the quarter. The company announced a new $1.5 billion share repurchase authorization in July 2024.
Nexstar CEO Perry A. Sook said, &#8221;During the quarter, we made further progress on our strategy for The CW, reducing operating losses by $36 million year-over-year and by $119 million year-to-date.&#8221;
&#8221;We debuted NASCAR Xfinity Series racing in September and WWE NXT wrestling in October on The CW broadcast network to double-digit percentage increases both in total audience and in adults 18-49 versus previous viewership on cable.&#8221;
Investors can gain exposure to the stock via&nbsp;LeaderShares AlphaFactor Tactical Focused ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSAT#NYSE">LSAT</a>) and Northern Lights Fund Trust IV Monarch Dividend Plus Index ETF (MDPL).
Price Action: Nexstar shares are up 2.92% at $188.60 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41815459" target="_blank" rel="noreferrer noopener">Rockwell Automation&#8217;s Mixed&nbsp;Q4: EPS&nbsp;Beats&nbsp;Amid 21%&nbsp;Sales Drop And Cautious FY25&nbsp;Outlook</a></li>
</ul>
Image:

Mid Cap

LSAT

NXST

Nexstar Media Q3: Political Ads, Distribution Gains Drive 21% Revenue Growth

Donald Trump's 2024 presidential win could prompt his hush money trial sentencing to be dismissed before the <a href="https://www.benzinga.com/general/politics/24/09/40754802/trump-hush-money-sentencing-will-now-take-place-after-2024-election-to-avoid-any-appearance-to-a">scheduled Nov. 26 date.</a>
What Happened: Trump <a href="https://www.benzinga.com/general/politics/24/05/39100065/trump-found-guilty-on-all-34-counts-in-hush-money-criminal-trial-heres-what-happens-next">was found guilty </a>on 34 counts of falsified business records in May in a New York trial known as the hush money trial.
Key witness testimony from former lawyer Michael Cohen and adult actress Stormy Daniels led to the 12-person jury finding Trump guilty on all 34 counts.
Sentencing was originally planned for July, but <a href="https://www.benzinga.com/general/politics/24/07/39609026/donald-trump-hush-money-trial-sentencing-delayed-to-september-18-the-supreme-court-immunity-impa">was delayed </a>by Judge Juan Merchan to Sept. 18 due to a Supreme Court ruling that granted partial immunity to Trump.
Judge Merchan postponed the sentencing from September to Nov. 26 to distance the trial from the 2024 election.
With Trump winning, legal experts now believe Merchan will call off the sentencing.
"I think any reasonable judge wouldn't sentence the president-elect," retired New York trial judge Jill Konviser said, as <a href="https://www.politico.com/news/2024/11/06/trump-sentencing-probably-wont-happen-00187999">reported </a>by Politico.
Set to be inaugurated as president in January, legal experts say Trump could argue that any sentencing, whether it be jail, home confinement or community service would interfere with his upcoming presidential duties.
Former Manhattan assistant district attorney Jeremy Saland doesn't see the sentencing moving ahead.
"The former president/president-elect does not get sentenced," Saland told Politico.
Former prosecutor Neama Rahmani said Merchan may not "have the stomach to imprison a former president or president-elect,&#8221; as <a href="https://nypost.com/2024/11/07/us-news/judge-in-trumps-hush-money-trial-considers-tossing-felony-conviction/">reported </a>by the New York Post. 
"Now that Trump has won, his criminal problems go away," Rahmani said.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110724">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: Judge Merchan will be tasked with sentencing in the case if nothing changes. Each of the 34 counts of which Trump was found guilty comes with a punishment of up to four years in prison. Trump is unlikely to receive prison time due to having no criminal record.
The sentence is also <a href="https://www.usatoday.com/story/news/factcheck/2024/05/31/trump-prison-time-fact-check/73916922007/">limited </a>to the total number of years Trump could face in prison, with New York limiting consecutive sentences for Class E felonies to a maximum of 20 years.
While he may not face prison time, a sentence of probation or home confinement could still occur and come ahead of inauguration day.
One option for Merchan would be to continue with the planned sentencing on Nov. 26 and any ruling would be deferred until 2029 when Trump is out of the White House. Merchan could also delay the sentencing until Trump is out of office.
The hush money trial is not the only case against Trump, with three other criminal cases currently pending. Each of these cases could also be closed after Trump's 2024 election victory.
Merchan also has to rule on a request by Trump for the guilty verdict to be thrown out after the Supreme Court ruling on presidential immunity. That ruling is currently scheduled for Nov. 12 and could make the Nov. 26 sentencing a non-issue.
While any prison sentence would complicate Trump&#8217;s presidency, there are <a href="https://www.benzinga.com/news/23/07/33446444/donald-trump-will-still-run-for-president-if-convicted-and-right-now-thats-perfectly-legal" target="_blank" rel="noopener">no current rule</a><a href="https://www.benzinga.com/news/23/07/33446444/donald-trump-will-still-run-for-president-if-convicted-and-right-now-thats-perfectly-legal">s</a> against running for president or even being president if incarcerated.
Trump <a href="https://www.benzinga.com/m-a/23/08/33878846/trump-to-maintain-control-of-media-company-if-he-sells-majority-goes-to-jail-or-becomes-president">will also maintain control </a>of his company Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) if he is sentenced to prison.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/11/41784933/donald-trumps-wealth-soars-with-2024-election-win-heres-how-much-president-elect-is-worth-ho">Donald Trump&#8217;s Wealth Soars With 2024 Election Win: Here&#8217;s How Much President-Elect Is Worth, How Much He&#8217;ll Make In White House</a></li>
</ul>
Photo: Shutterstock

Politics

Legal

Will Trump Be Sentenced In Hush Money Trial Or Will His 'Criminal Problems Go Away'?

WIIM

TRNR

Interactive Strength shares are trading lower after the company announced a 1-for-100 reverse split.

Wendy&#8217;s Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) is using artificial intelligence from data analytics firm Palantir Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) to manage its supply of <a href="https://www.benzinga.com/general/restaurants/24/10/41149776/wendys-is-ready-kids-and-adults-spongebob-squarepants-collaboration-includes-pineapple-frosty">burgers, fries and Frosty's.</a> 
The Details: Wendy's supply chain purchases are handled by an independent co-op group that first tested Palantir's technology last year amid tight profit margins and increasing pressure from inflation, according to a Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-11-07/wendy-s-wen-1-frosty-deal-made-easier-with-ai-from-palantir-pltr?sref=TBDibEcD">report.</a> The group is using Palantir's system to spot shortages and suggest solutions like placing an order from a supplier. 
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
Pete Suerken, who leads the purchasing co-op, said the system's AI learns over time and can suggest a specific warehouse, after considering factors such as cost and the probability of the items arriving on time. The software <a href="https://www.benzinga.com/markets/equities/24/08/40220301/whats-going-on-with-palantir-stock-today">can predict</a> when specific products will run out by analyzing current and historical sales figures.&nbsp;
Suerken praised Palantir's platform and said it was "so much better" than spreadsheets and other customary inventory management methods. He also said the return on investment is "significant." 
Wendy's recently asked the supply chain program to identify shortages restaurants could face over the following three weeks and then staff trained the model by showing how the shortages should be solved. Wendy's purchasing group plans to eventually allow the AI model to manage smaller inventory and ordering tasks autonomously and without human intervention. 
"Three or four years from now, if you're not doing this, you'll be at a distinct disadvantage," said Suerken. "This is something that, as an industry, will change the way we work."&nbsp;
WEN, PLTR Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Wendy's shares are down 1.54% at $20.08 and Palantir shares are down 2.13% at $54.32 at the time of publication Thursday. 
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41561955/dollar-general-aims-to-draw-customers-from-walmart-amazon-with-holiday-sales-events">Dollar General Aims To Draw Customers From Walmart, Amazon With Holiday Sales Events</a></li>
</ul>
Photo: Shutterstock

Restaurants

Tech

PLTR

Wendy's Uses Palantir AI Tech To Manage Burger, French Fry Inventories; Return On Investment Is 'Significant'

Lion Electric shares are trading lower after the company reported worse-than-expected Q3 financial results.

RBC Capital analyst Piral Dadhania maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Sector Perform and lowers the price target from $82 to $80.

RBC Capital Maintains Sector Perform on Nike, Lowers Price Target to $80

CHRS

Coherus BioSciences shares are trading higher after the company reported better-than-expected Q3 financial results.

BRDG

Bridge Investment Group shares are trading lower after the company reported worse-than-expected Q3 adjusted EPS results.

IHRT

iHeartMedia shares are trading higher after the company announced better-than-expected Q4 sales guidance.

CEVA

CEVA shares are trading higher after the company reported better-than-expected Q3 financial results and approved an increase to the buyback program by 700k shares.

RBC Capital analyst Scott Heleniak maintains NMI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMIH#NASDAQ">NMIH</a>) with a Outperform and lowers the price target from $48 to $47.

NMIH

RBC Capital Maintains Outperform on NMI Holdings, Lowers Price Target to $47

Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.12) by 91.67 percent. The company reported quarterly sales of $70.77 million which beat the analyst consensus estimate of $59.23 million by 19.49 percent. This is a 5.09 percent decrease over sales of $74.57 million the same period last year.

Earnings Beats

Reported November 6: Coherus BioSciences Q3 2024 Adj EPS $(0.01) Beats $(0.12) Estimate, Sales $70.77M Beat $59.23M Estimate

AUPH

Aurinia Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and announced a workforce reduction.

UPWK

Upwork shares are trading higher after multiple firms maintained Buy ratings on the stock and raised their respective price targets.

Fulcrum crashes as GSK-partnered lead program fails

Stifel Nicolaus analyst Dae Gon Ha maintained a Buy rating on Fulcrum Therapeutics (FULC – Research Report) today and set a price target of $22.00....

Stifel Nicolaus Keeps Their Buy Rating on Fulcrum Therapeutics (FULC)

Fulcrum downgraded after setback for lead program (update)

Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly

In a report released on September 11, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Fulcrum Therapeutics (FULC – Research Report...

Buy Rating on Fulcrum's Losmapimod: Navigating FSHD Treatment Potential Despite Phase 2 Challenges

Fulcrum Therapeutics (FULC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein fro...

Hold Rating on Fulcrum Therapeutics Amid Phase 3 Drug Failure and Pivot to Sickle Cell Disease Candidate

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Sept. 9-13, 2024.

Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14

Fulcrum reduces its workforce

Stifel Nicolaus analyst Dae Gon Ha maintained a Hold rating on Fulcrum Therapeutics (FULC – Research Report) today and set a price target of $3.00....

Fulcrum Therapeutics (FULC) Gets a Hold from Stifel Nicolaus

Fulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setback

CVNA

FULC

MRNA

ORCL

ROKU

SNYNF

ULTA

Press Releases

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!

Comments

Fulcrum Therapeutics

Notizie

Ultime notizie per Fulcrum Therapeutics (NASDAQ:FULC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO